Article
Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
International journal of hematology - 1 May 2006
Kiyoi Hitoshi, Naoe Tomoki
Abstract excerpt
Overexpression and activating mutations of receptor tyrosine kinases (RTKs) are known to be involved in the pathophysiology of several kinds of cancer cells. FMS-like receptor tyrosine kinase 3 (FLT3), together with KIT, FMS, and platelet-derived growth factor receptor, is a class III RTK. FLT3 mutations were first reported as internal tandem duplication (FLT3/ITD) of the juxtamembrane domain-coding sequence;...
Topics
- Acute Disease
- Cell Differentiation
- Cell Proliferation
- Drug Design
- Enzyme Activation
- Gene Expression Regulation, Leukemic
- Humans
- Leukemia, Myeloid, Acute
- Leukocytosis
- Mutation
- Prognosis